Why Momenta Stalled

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Momenta Pharmaceuticals (Nasdaq: MNTA  ) were down more than 8% today after a massive double miss that was blamed on weak royalty revenue.

So what: Momenta reported a $0.51 loss per share on revenues of just $5.1 million, both significantly lower than the Street's consensus figures that called for $0.27 in losses per share on $16.5 million in quarterly revenue. The company's 2013 guidance, which projects a cash burn of about $90 million for the full year, seems to assure another year of hemorrhaging unprofitability.

Now what: No investor likes to hear that a CEO was disappointed in his company's results, but Momenta CEO Craig Wheeler said just that when discussing the lackluster royalties earned by enoxaparin sodium injections. Whether it's the result of "a more competitive multi-player dynamic," as Wheeler suggested, or simply a lack of sufficient interest in Momenta's products, it's tough to call a buying opportunity when Momenta remains highly valued speculative biotech company with minuscule revenue. Until Momenta starts advancing another drug with better prospects through the FDA approval process, there seems little reason to invest.

Want more news and updates? Add Momenta Pharmaceuticals to your Watchlist now.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2100853, ~/Articles/ArticleHandler.aspx, 10/24/2014 8:30:41 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 11 hours ago Sponsored by:
DOW 16,677.90 216.58 1.32%
S&P 500 1,950.82 23.71 1.23%
NASD 4,452.79 69.95 1.60%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/23/2014 3:59 PM
MNTA $11.00 Up +0.34 +3.19%
Momenta Pharmaceut… CAPS Rating: ****

Advertisement